No abstract

Benign prostatic hyperplasia (BPH) is a common problem in aging menof BPH include increased urinary frequency, urgency, intermittency; nocturia; decreased force of stream; hesitancy and straining that are usually associated with complications such as acute urinary retention, urinary incontinence, recurrent urinary tract infection, hematuria, renal failure, and bladder stone. [4][5][6][7][8][9] The primary goal for treating symptomatic BPH is to improve urine ß ow, for which both surgical and nonsurgical approaches are available. Surgical treatment for BPH is usually indicated in recurrent cases of urinary retention, urinary tract infections, hematuria, and in azotemia.

No abstract

Arthritis is a joint disorder where the joint damage is associated with elevated levels of inflammatory mediators and reactive oxygen species (ROS). The inflammatory hyperalgesia associated with arthritis has been shown to be attenuated by anti-hyperlipidemic drug, atorvastatin. The present study was carried out to evaluate the effect of atorvastatin on joint inflammation and associated oxidative stress markers in a rat model where arthritis was induced by intra-articular injection of 0.1 ml of 0.1% Freund's Complete Adjuvant (FCA). Atorvastatin (10 mg and 50 mg/kg) and diclofenac (5 mg/kg) were administered orally, daily during the study period of 4 days and their effect on joint inflammation was evaluated by measuring joint diameter, levels of glutathione (GSH), thiobarbituric acid reactive substances (TBARS), activity of super oxide dismutase (SOD) and tissue histology. Atorvastatin produced a dose-dependent reduction in joint inflammation that was associated with normalization of levels of oxidative stress markers and tissue histology and its effect was found to be comparable to that of diclofenac.

After publication of this work an overlap in the values of increase in joint diameter on day 3 in different groups and panel a of Fig. 3 with those in our previous paper (Wahane and Kumar 2010) was brought to our attention. These studies were part of the same project and this error resulted due to an oversight. Day 3 values for increase in joint diameter for the original article are-FC: 4.24 ± 0.13 mm; D5: 3.10 ± 0.09 mm; A10: 3.48 ± 0.12 mm; A50: 2.87 ± 0.11 mm (27, 18 and 32 % inhibition, respectively). Panel a of Fig. 3 was used for reference purpose in these papers.This correction does not affect the conclusion of the study.The authors apologize for this error and any inconvenience caused. ReferenceWahane VD, Kumar VL (2010) Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis.